Biotechnology Assets (STU:041) NonCurrent Deferred Liabilities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:041 Biotechnology Assets SA STU:041
19 GF Score
Price €0.25
GF Value €0.36
! 3 Warning Signs
View Full Analysis

What is Biotechnology Assets NonCurrent Deferred Liabilities?

Biotechnology Assets STU:041 19 NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus rates STU:041 with a GF Score™ of 19/100 and a GF Value™ of €0.36. The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Biotechnology Assets's non-current deferred liabilities for the quarter that ended in Dec. 2025 was €0.00 Mil.

Biotechnology Assets NonCurrent Deferred Liabilities Related Terms

Biotechnology Assets NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Biotechnology Assets's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotechnology Assets NonCurrent Deferred Liabilities Chart

Biotechnology Assets Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biotechnology Assets Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:041
19GF Score
Biotechnology Assets SA STU:041
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
Biotechnology Assets (STU:041) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Biotechnology Assets and its competitors.
Is Biotechnology Assets' NonCurrent Deferred Liabilities too high?
Biotechnology Assets' current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, Biotechnology Assets has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' NonCurrent Deferred Liabilities compare to VRTX and REGN?
Biotechnology Assets' NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Biotechnology Assets (STU:041) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The stock's GF Value™ is €0.36, compared to a current price of €0.25 — trading 29.7% below its estimated fair value. The current NonCurrent Deferred Liabilities is €0.00 Mil. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Biotechnology Assets (STU:041), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biotechnology Assets (STU:041) Overvalued in 2026?

Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued. The current stock price of €0.25 is trading 29.7% below its estimated GF Value™ of €0.36.

Key valuation signals for STU:041:

  • NonCurrent Deferred Liabilities: €0.00 Mil
  • GF Value™: €0.36 vs. price of €0.25 (29.7% below fair value)
  • GF Score™: 19/100 with 3 warning signs

No single metric tells the full story. See the STU:041 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biotechnology Assets Business Description

Other Exchanges BST:Spain
Address Avenida del Desarrollo Tecnologico, No. 11, Scientific and Technological Park, Jerez de la Frontera, ESP, 11591
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score

Get the complete analysis for STU:041

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.36
GF Value